Men's Health News

RSS
Study shows only 44% of black males prefer to be investigated for prostate cancer

Study shows only 44% of black males prefer to be investigated for prostate cancer

Ninety percent of patients at risk of CHD fail to receive statins

Ninety percent of patients at risk of CHD fail to receive statins

NICE recommends transurethral resection in saline system as the new gold standard for transurethral resection of the prostate

NICE recommends transurethral resection in saline system as the new gold standard for transurethral resection of the prostate

Life-saving bone marrow transplants are not available to all who need them

Life-saving bone marrow transplants are not available to all who need them

Loyola physician reveals top five health concerns for men, offers tips to prevent them

Loyola physician reveals top five health concerns for men, offers tips to prevent them

Deadly C. difficile affected almost half a million in the U.S over one year

Deadly C. difficile affected almost half a million in the U.S over one year

Psoriasis management: an interview with Dr Sandy McBride

Psoriasis management: an interview with Dr Sandy McBride

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

PCF announces Challenge Awards to support research on new treatment strategies for prostate cancer

PCF announces Challenge Awards to support research on new treatment strategies for prostate cancer

Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

Nuo Therapeutics initiates phase 4 study of Aurix™ under CMS coverage with evidence development program

MD Anderson awarded more than $22 million in research grants from CPRIT

MD Anderson awarded more than $22 million in research grants from CPRIT

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

Ready to reconstitute BPW adds convenient option to support high throughput Salmonella testing in chocolate production

Ready to reconstitute BPW adds convenient option to support high throughput Salmonella testing in chocolate production

Scientists identify promising new therapeutic target for prostate cancer

Scientists identify promising new therapeutic target for prostate cancer

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Sugar intake and tooth decay: an interview with Professor Nigel Pitts

Sugar intake and tooth decay: an interview with Professor Nigel Pitts

The growing evidence on  standardised packaging of tobacco products

The growing evidence on standardised packaging of tobacco products

Cabazitaxel therapy may be more effective in treating prostate cancer

Cabazitaxel therapy may be more effective in treating prostate cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.